Nuvation Bio Inc.

NUVB | NYSE

Price Alert Chart Builder DCF Calculator

$6.07

+$0.22 (+3.76%)

At close: Sep 21, 2026, 4:00 PM ET

$6.08

+$0.01 (+0.16%)

Pre-market: Sep 22, 2026, 4:25 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+3.76%

(1D)

Rating

Updated: Aug 10, 2026

23.1

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $2.11B

1D Range

5.95 6.11

52W Range

2.99 9.75

Valuation (TTM)

PE -13.80

PB 8.30

EV/EBITDA -13.37

Valuation (NTM)

Forward PE N/A

Forward PEG 0.28

Price Target $20.50

Cash Flow

FCF Yield -3.9%

SBC Adj. FCF Yield -3.0%

SBC Impact -24.0%

Margins

Gross Margin 93.9%

Operating Margin -81.0%

FCF Margin -48.7%

Growth (CAGR)

Revenue 3Y | 5Y 136.1% | 95.4%

Dil EPS 3Y | 5Y 78.8% | -1.5%

FCF 3Y | 5Y 0.7% | -7.4%

Returns

ROA -20.1%

ROE -49.7%

ROIC -20.7%

Financial Health

Net Cash

$410.53M

Current Ratio 8.37

Interest Coverage -5.16

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound...

Sector Healthcare

Industry Biotechnology

Employees 305

IPO Date Aug 25, 2020

Website www.nuvationbio.com

Fiscal Year January - December

Full Company Profile

Latest News

5 days ago · prnewswire.com

Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer

Updated label reflects TRUST-I TKI-naïve median duration of response of nearly 50 months No changes to the safety sections of labeling with longer follow-up and no new safety signals identified Approval comes four months ahead of PDUFA date NEW YORK, Sept. 16, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for IBTROZI® (taletrectinib), a ROS1 inhibitor approved for the treatment of locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC).

7 days ago · seekingalpha.com

Nuvation Bio Inc. (NUVB) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

7 days ago · prnewswire.com

Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer

Long-term pooled data from the pivotal TRUST-I and TRUST-II studies showed similar efficacy, including duration of response and progression-free survival, between CD74 and non-CD74 ROS1 fusion-partner subgroups Among patients who received IBTROZI after prior chemotherapy, response rates remained consistent, offering reassurance for patients who begin chemotherapy before a ROS1 fusion is identified NEW YORK, Sept. 15, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced new subgroup analyses from the pivotal TRUST-I and TRUST-II studies evaluating IBTROZI® (taletrectinib) in both TKI- naïve and TKI-pretreated patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC).

13 days ago · seekingalpha.com

Nuvation Bio Inc. (NUVB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

18 days ago · benzinga.com

Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Nuvation Bio Inc. (NYSE:NUVB) is a “pure spec.”

19 days ago · zacks.com

Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in Nuvation Bio (NUVB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

20 days ago · prnewswire.com

Nuvation Bio to Participate in Upcoming Investor Conferences

NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D.

22 days ago · zacks.com

Nuvation Bio (NUVB) Upgraded to Buy: Here's Why

Nuvation Bio (NUVB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago · zacks.com

Wall Street Analysts Predict a 105.71% Upside in Nuvation Bio (NUVB): Here's What You Should Know

The mean of analysts' price targets for Nuvation Bio (NUVB) points to a 105.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.